Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working …
PM LoRusso, K Venkatakrishnan, RK Ramanathan… - Clinical Cancer …, 2012 - AACR
Purpose: The proteasome inhibitor bortezomib undergoes oxidative hepatic metabolism.
This study (NCI-6432; NCT00091117) was conducted to evaluate bortezomib
pharmacokinetics and safety in patients with varying degrees of hepatic impairment, to
inform dosing recommendations in these special populations. Experimental Design: Patients
received bortezomib on days 1, 4, 8, and 11 of 21-day cycles. Patients were assigned to four
hepatic function groups based on the National Cancer Institute Organ Dysfunction Working …
This study (NCI-6432; NCT00091117) was conducted to evaluate bortezomib
pharmacokinetics and safety in patients with varying degrees of hepatic impairment, to
inform dosing recommendations in these special populations. Experimental Design: Patients
received bortezomib on days 1, 4, 8, and 11 of 21-day cycles. Patients were assigned to four
hepatic function groups based on the National Cancer Institute Organ Dysfunction Working …
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: results of the Phase 1 National Cancer …
K Venkatakrishnan, RK Ramanathan, J Sarantopoulos… - Blood, 2010 - Elsevier
Abstract Abstract 3975 Background: Bortezomib (btz, VELCADE®) is approved in the US for
the treatment of patients (pts) with multiple myeloma, and for the treatment of pts with mantle
cell lymphoma who have received at least one prior therapy. Btz is oxidatively metabolized
by hepatic cytochrome P450 enzymes to pharmacologically inactive deboronated
metabolites. Thus, btz pharmacokinetics (PK) may be altered in pts with hepatic impairment
(HI). This phase 1 study was undertaken to evaluate the PK and safety of btz in pts with …
the treatment of patients (pts) with multiple myeloma, and for the treatment of pts with mantle
cell lymphoma who have received at least one prior therapy. Btz is oxidatively metabolized
by hepatic cytochrome P450 enzymes to pharmacologically inactive deboronated
metabolites. Thus, btz pharmacokinetics (PK) may be altered in pts with hepatic impairment
(HI). This phase 1 study was undertaken to evaluate the PK and safety of btz in pts with …
以上显示的是最相近的搜索结果。 查看全部搜索结果